Setara Biosciences began with $90 million in funding and a lead program in the clinic, combining rare disease focus with a second, more common therapeutic target. The company’s lead small-molecule candidate is being developed for Charcot-Marie-Tooth disease type 2C and overactive bladder. Setara’s pipeline traces back to Actio Biosciences, which Jazz Pharmaceuticals recently acquired, linking Setara’s early-stage assets to post-M&A program development and reinvestment. The company’s lead drug is positioned as its near-term clinical anchor. With $90 million at launch, Setara can support early clinical operations and platform maturation while pursuing additional programs downstream. The dual-indication setup also suggests the company is aiming for a balance between high-need rare disease development and a larger patient base through overactive bladder. The clinic entry provides the company a way to convert investor backing into clinical milestones quickly, which can be especially important for early-stage biotechs competing for later-stage attention.